All Trials

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic, pMMR/MSS colorectal adenocarcinoma (no liver or CNS metastases, ECOG 0-1, no prior systemic therapy for metastatic disease) to evaluate the addition of volrustomig—a bispecific anti-PD-1/CTLA-4 antibody—to FOLFIRI and bevacizumab versus standard FOLFIRI plus bevacizumab. Volrustomig is designed to enhance immune response by targeting CTLA-4 selectively on PD-1+ T cells.

ClinicalTrials.gov ID: NCT06792695

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic, anti-EGFR-refractory, KRAS/NRAS/BRAF V600E/EGFR WT advanced colorectal cancer (progressed on EGFR antibody and standard chemotherapy), and treats them with avutometinib (a dual RAF/MEK inhibitor), defactinib (FAK inhibitor), and cetuximab. Prior BRAF/MEK/ERK inhibitor therapy and active CNS metastases are exclusion criteria.

ClinicalTrials.gov ID: NCT06369259

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic colorectal cancer (ECOG 0-1) and tests combinations of telisotuzumab adizutecan, a c-Met–targeting antibody-drug conjugate linked to a topoisomerase I inhibitor, with standard regimens (FOLFOX plus bevacizumab or 5-FU/LV plus panitumumab) versus standard therapy alone, excluding patients with prior c-Met or topoisomerase inhibitor treatment.

ClinicalTrials.gov ID: NCT06820463

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors that have progressed after standard therapies, enrolled in tumor-specific refractory cohorts (e.g., melanoma post–PD-(L)1, SCCHN post platinum/PD-(L)1, HER2-negative gastric/GEJ, HGS ovarian, cervical, endometrial, urothelial, ESCC, pancreatic, mCRPC, nonsquamous NSCLC without drivers, and HR+/HER2– breast cancer after CDK4/6 and chemo). Single-arm therapy is patritumab deruxtecan (HER3-DXd) 5.6 mg/kg IV q3w, an HER3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd).

ClinicalTrials.gov ID: NCT06172478

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated, locally advanced unresectable or metastatic EGFR-mutated non-squamous NSCLC (ECOG 0–1) are randomized to telisotuzumab adizutecan (c-Met–targeting ADC delivering a topoisomerase I inhibitor) plus fixed-dose osimertinib versus comparator regimens (osimertinib alone in Phase 2; standard of care in Phase 3), with c-Met IHC–based stratification. Key exclusions include prior/active ILD, leptomeningeal disease, and uncontrolled spinal cord compression.

ClinicalTrials.gov ID: NCT07005102

DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory extensive-stage SCLC (post ≥2 lines including platinum and, where standard, PD‑L1 inhibitor) or other high‑grade neuroendocrine carcinomas (including pulmonary LCNEC and DLL3‑high extrapulmonary NEC after ≥1 platinum) receive intravenous BI 764532, a DLL3/CD3 bispecific T‑cell engager redirecting T‑cell cytotoxicity to DLL3‑expressing tumors. Part 1 randomizes between two dose levels; Part 2 expands at the selected dose in centrally confirmed DLL3‑high extrapulmonary NEC.

ClinicalTrials.gov ID: NCT05882058

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Untreated adults with extensive-stage SCLC (ECOG 0–1), including those with treated/stable brain metastases, receive induction platinum–etoposide plus durvalumab followed by maintenance durvalumab with ceralasertib. Ceralasertib is an oral ATR kinase inhibitor targeting the DNA damage response to potentiate cytotoxic and PD-L1–directed immunotherapy.

ClinicalTrials.gov ID: NCT04699838

A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed SCLC after platinum-based first-line therapy (≤2 prior cytotoxic lines; ECOG 0–2; measurable disease; treated/stable CNS mets allowed) receive oral onvansertib, a selective ATP-competitive PLK1 inhibitor that induces G2/M arrest and apoptosis, given days 1–14 of 21-day cycles. Single-arm design with potential biomarker enrichment (e.g., TP53 mutation type, SCLC-Y, MYC expression); primary endpoint is objective response.

ClinicalTrials.gov ID: NCT05450965

A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with newly diagnosed, IDH-wild type, MGMT-unmethylated GBM post-radiotherapy (ECOG 0–2) receive Sonocloud-9–mediated blood–brain barrier opening every 3 weeks synchronized with liposomal doxorubicin plus balstilimab (anti–PD-1) and botensilimab (Fc‑enhanced anti–CTLA‑4). Excludes prior immunotherapy, multifocal/not-coverable or posterior fossa disease, active autoimmune disease, and other major comorbidities.

ClinicalTrials.gov ID: NCT05864534

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases (EBVision)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling children and adults with EBV-positive disorders who lack suitable first-line options or have relapsed/refractory disease, including PID/AID-associated EBV+ LPD, CNS-involved EBV+ PTLD, PTLD where rituximab/chemotherapy is inappropriate (including CD20‑negative), and rapidly progressive EBV+ sarcomas. Participants receive tabelecleucel, an allogeneic, partially HLA‑matched EBV‑specific cytotoxic T‑cell therapy targeting EBV antigens (EBNA/LMP), given IV on Days 1, 8, and 15 of 35‑day cycles until response or progression.

ClinicalTrials.gov ID: NCT04554914